

# Chun Jen Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5364014/publications.pdf>

Version: 2024-02-01

335  
papers

17,547  
citations

18482  
62  
h-index

18647  
119  
g-index

341  
all docs

341  
docs citations

341  
times ranked

12703  
citing authors

#	ARTICLE	IF	CITATIONS
1	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	4.2	1,908
2	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , 2012, 6, 531-561.	4.2	874
3	Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1348-1355.	6.3	534
4	Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men. <i>Journal of the National Cancer Institute</i> , 2005, 97, 265-272.	6.3	518
5	Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan. <i>Gastroenterology</i> , 2008, 135, 111-121.	1.3	492
6	High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load. <i>Gastroenterology</i> , 2012, 142, 1140-1149.e3.	1.3	469
7	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85.	2.8	358
8	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
9	The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e186.	5.1	319
10	High Prevalence and Mapping of Pre-S Deletion in Hepatitis B Virus Carriers With Progressive Liver Diseases. <i>Gastroenterology</i> , 2006, 130, 1153-1168.	1.3	257
11	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. <i>Hepatology</i> , 2013, 57, 441-450.	7.3	227
12	Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. <i>Gastroenterology</i> , 2009, 136, 496-504.e3.	1.3	211
13	Familial Risk of Hepatocellular Carcinoma Among Chronic Hepatitis B Carriers and Their Relatives. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1159-1164.	6.3	200
14	Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. <i>Journal of Hepatology</i> , 2004, 41, 659-666.	3.7	194
15	Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. <i>Gastroenterology</i> , 2016, 151, 472-480.e1.	1.3	187
16	Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. <i>Gastroenterology</i> , 2011, 141, 517-525.e2.	1.3	184
17	Pegylated Interferon-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 1260-1269.	5.8	177
18	Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1555-1560.	2.8	174

#	ARTICLE	IF	CITATIONS
19	Role of Hepatitis B Viral Load and Basal Core Promoter Mutation in Hepatocellular Carcinoma in Hepatitis B Carriers. <i>Journal of Infectious Diseases</i> , 2006, 193, 1258-1265.	4.0	163
20	Global Perspective on the Natural History of Chronic Hepatitis B: Role of Hepatitis B Virus Genotypes A to J. <i>Seminars in Liver Disease</i> , 2013, 33, 097-102.	3.6	154
21	Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4587-4593.	1.6	150
22	Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. <i>Journal of Hepatology</i> , 2009, 50, 958-968.	3.7	144
23	Hepatitis C Virus Infection and Increased Risk of Cerebrovascular Disease. <i>Stroke</i> , 2010, 41, 2894-2900.	2.0	134
24	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. <i>Hepatology</i> , 2012, 55, 68-76.	7.3	130
25	Role of Hepatitis B Virus Precore/Core Promoter Mutations and Serum Viral Load on Noncirrhotic Hepatocellular Carcinoma: A Caseâ€Control Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 594-599.	4.0	125
26	Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study. <i>Gastroenterology</i> , 2017, 153, 1006-1017.e5.	1.3	123
27	Androgen-Receptor Gene CAG Repeats, Plasma Testosterone Levels, and Risk of Hepatitis B-Related Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2000, 92, 2023-2028.	6.3	121
28	Body-Mass Index and Progression of Hepatitis B: A Population-Based Cohort Study in Men. <i>Journal of Clinical Oncology</i> , 2008, 26, 5576-5582.	1.6	119
29	The Asiaâ€Pacific Working Party on Nonâ€alcoholic Fatty Liver Disease guidelines 2017â€Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98.	2.8	117
30	Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. <i>Hepatology</i> , 2003, 37, 568-576.	7.3	111
31	Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. <i>Gut</i> , 2007, 57, 91-97.	12.1	108
32	Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NAT. <i>Journal of Clinical Virology</i> , 2006, 36, S33-S44.	3.1	105
33	Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. <i>Journal of Hepatology</i> , 2006, 44, 39-46.	3.7	105
34	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. <i>Gut</i> , 2015, 64, 292-302.	12.1	105
35	Hepatitis B viral factors in HBeAg-Negative carriers with persistently normal serum alanine aminotransferase levels. <i>Hepatology</i> , 2007, 45, 1193-1198.	7.3	103
36	Hepatitis B viral genotypes and lamivudine resistance. <i>Journal of Hepatology</i> , 2002, 36, 303-304.	3.7	102

#	ARTICLE	IF	CITATIONS
37	Polymorphisms in XRCC1 and Glutathione S-Transferase Genes and Hepatitis B-Related Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1485-1488.	6.3	100
38	Therapeutic implications of hepatitis B virus genotypes. <i>Liver International</i> , 2005, 25, 1097-1107.	3.9	100
39	Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. <i>International Journal of Epidemiology</i> , 2005, 34, 1310-1318.	1.9	99
40	Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 197-203.	6.0	98
41	RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. <i>Gastroenterology</i> , 2005, 128, 708-716.	1.3	97
42	Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. <i>Gastroenterology</i> , 2018, 154, 989-997.	1.3	97
43	Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. <i>Hepatology</i> , 2003, 38, 1393-1400.	7.3	96
44	Viral hepatocarcinogenesis: from infection to cancer. <i>Liver International</i> , 2008, 28, 175-188.	3.9	95
45	Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon-Î±2A Therapy. <i>Antiviral Therapy</i> , 2011, 16, 629-637.	1.0	91
46	Pegylated Interferon-Î±2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.	3.9	91
47	Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 779-782.	2.8	88
48	High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. <i>Liver International</i> , 2008, 28, 271-277.	3.9	86
49	High Level of Hepatitis B Coreâ€‘Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. <i>Gastroenterology</i> , 2019, 157, 1518-1529.e3.	1.3	83
50	Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. <i>Carcinogenesis</i> , 2008, 29, 106-112.	2.8	81
51	Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 1133-1139.	1.0	80
52	Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1057-1065.	4.5	77
53	Comparison of a 6â€‘month course peginterferon Î±2b plus ribavirin and interferon Î±2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. <i>Journal of Viral Hepatitis</i> , 2005, 12, 283-291.	2.0	73
54	Pegylated interferon Î±2a versus standard interferon Î±2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. <i>Gut</i> , 2007, 57, 525-530.	12.1	69

#	ARTICLE	IF	CITATIONS
55	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association, 2020, 119, 1135-1157.	1.7	69
56	A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. Gastroenterology, 2003, 124, 80-90.	1.3	68
57	Hepatitis B Virus-related Hepatocellular Carcinoma: Epidemiology and Pathogenic Role of Viral Factors. Journal of the Chinese Medical Association, 2007, 70, 141-145.	1.4	67
58	Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut, 2013, 62, 182.2-184.	12.1	67
59	Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. Journal of Infectious Diseases, 2018, 217, 1193-1201.	4.0	67
60	Community and personal risk factors for hepatitis C virus infection: a survey of 23 820 residents in Taiwan in 1991-2. Gut, 2011, 60, 688-694.	12.1	66
61	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology, 2013, 57, 2135-2142.	7.3	66
62	Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. Molecular Therapy - Nucleic Acids, 2020, 20, 480-490.	5.1	66
63	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7243-7248.	7.1	65
64	Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. Journal of Hepatology, 2005, 43, 235-242.	3.7	64
65	Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e95870.	2.5	64
66	Taiwan consensus statement on the management of chronic hepatitis B. Journal of the Formosan Medical Association, 2019, 118, 7-38.	1.7	64
67	Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping. Journal of Clinical Microbiology, 2015, 53, 1754-1757.	3.9	62
68	Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis. International Journal of Molecular Sciences, 2014, 15, 10578-10604.	4.1	60
69	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association, 2020, 119, 1019-1040.	1.7	60
70	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7844-7849.	7.1	57
71	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3719-3724.	7.1	56
72	Impact of hepatitis B virus infection on metabolic profiles and modifying factors. Journal of Viral Hepatitis, 2012, 19, e48-57.	2.0	56

#	ARTICLE	IF	CITATIONS
73	Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. <i>World Journal of Gastroenterology</i> , 2014, 20, 11384.	3.3	55
74	Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. <i>Carcinogenesis</i> , 2011, 32, 876-881.	2.8	53
75	Influences of tobacco and alcohol use on hepatocellular carcinoma survival. <i>International Journal of Cancer</i> , 2012, 131, 2612-2621.	5.1	52
76	Low incidence of hepatitis C virus transmission between spouses: A prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 391-395.	2.8	51
77	Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters. <i>Journal of Infectious Diseases</i> , 2012, 205, 54-63.	4.0	51
78	Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. <i>Hepatology</i> , 2001, 34, 583-589.	7.3	50
79	Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 64-71.	4.4	50
80	Dual chronic hepatitis B virus and hepatitis C virus infection. <i>Hepatology International</i> , 2009, 3, 517-525.	4.2	49
81	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 949-960.	3.7	49
82	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. <i>Journal of Hepatology</i> , 2020, 72, 839-846.	3.7	49
83	Treatment of patients with dual hepatitis C and B by peginterferon $\alpha$ and ribavirin reduced risk of hepatocellular carcinoma and mortality. <i>Gut</i> , 2014, 63, 506-514.	12.1	48
84	Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. <i>Journal of Infectious Diseases</i> , 2012, 206, 1521-1531.	4.0	47
85	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013, 57, 934-943.	7.3	47
86	Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2013, 8, e53008.	2.5	47
87	Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 58-64.	1.2	47
88	HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. <i>Journal of Infectious Diseases</i> , 2010, 202, 86-92.	4.0	46
89	Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. <i>Hepatology International</i> , 2013, 7, 316-326.	4.2	46
90	Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 902-911.	3.7	46

#	ARTICLE	IF	CITATIONS
91	Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. <i>Hepatology</i> , 2015, 61, 1934-1944.	7.3	46
92	Risk Stratification of Hepatocellular Carcinoma in Hepatitis B Virus e Antigenâ€“Negative Carriers by Combining Viral Biomarkers. <i>Journal of Infectious Diseases</i> , 2013, 208, 584-593.	4.0	45
93	Significance of definitions of relapse after discontinuation of oral antivirals in HBeAgâ€“negative chronic hepatitis B. <i>Hepatology</i> , 2018, 68, 415-424.	7.3	45
94	Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1405-1413.	2.8	44
95	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017, 112, 1564-1574.	0.4	44
96	Genotypic dominance and novel recombinations in HBV genotype B and C coâ€“infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 73, 13-22.	5.0	43
97	Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx028.	0.9	43
98	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1105-1111.	3.7	43
99	Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis. <i>Journal of Medical Virology</i> , 2004, 72, 545-550.	5.0	42
100	Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 177-184.	1.0	42
101	Interferon Î±-2b with and without ribavirin in the treatment of hepatitis B e antigenâ€“positive chronic hepatitis B: A randomized study. <i>Hepatology</i> , 2006, 43, 742-749.	7.3	41
102	Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. <i>Genes and Immunity</i> , 2010, 11, 87-93.	4.1	41
103	Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2012, 17, 477-484.	1.0	41
104	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	7.3	41
105	Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: A 4-year experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 1001-1008.	2.8	40
106	Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: Correlation with viral serotypes and clinical stages of liver disease. <i>Journal of Medical Virology</i> , 2002, 68, 50-59.	5.0	40
107	High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 74, 536-542.	5.0	40
108	Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. <i>Liver International</i> , 2006, 26, 949-955.	3.9	40



#	ARTICLE	IF	CITATIONS
109	Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2002, 37, 283-287.	5.1	39
110	Natural Course and Treatment of Hepatitis D Virus Infection. <i>Journal of the Formosan Medical Association</i> , 2006, 105, 869-881.	1.7	39
111	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015, 64, 303-311.	12.1	39
112	Hepatitis B Virus Core Variants Modify Natural Course of Viral Infection and Hepatocellular Carcinoma Progression. <i>Gastroenterology</i> , 2009, 137, 1687-1697.	1.3	38
113	Hepatitis C viral infection increases the risk of lymphoid neoplasms: A population-based cohort study. <i>Hepatology</i> , 2016, 63, 721-730.	7.3	38
114	Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. <i>Journal of Clinical Investigation</i> , 2020, 130, 3205-3220.	8.2	38
115	Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. <i>Journal of the Formosan Medical Association</i> , 2005, 104, 783-91.	1.7	38
116	Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 705-713.	2.2	37
117	Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2021, 15, 451-458.	2.9	37
118	Genetic Variability of Hepatitis B virus and Response to Antiviral Therapy. <i>Antiviral Therapy</i> , 2008, 13, 613-624.	1.0	37
119	Pegylated Interferon Alfa-2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C. <i>Clinical Infectious Diseases</i> , 2010, 51, 541-549.	5.8	36
120	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	1.0	35
121	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.4	34
122	The clinical significance of occult hepatitis B transfusion in Taiwan – a look-back study. <i>Transfusion Medicine</i> , 2011, 21, 33-41.	1.1	34
123	Metabolic profiles in patients with chronic hepatitis C: a case-control study. <i>Hepatology International</i> , 2008, 2, 250-257.	4.2	33
124	The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. <i>Kidney International</i> , 2010, 78, 103-109.	5.2	32
125	Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. <i>International Journal of Epidemiology</i> , 2002, 31, 1008-1015.	1.9	31
126	High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2009, 3, 364-370.	4.2	31



#	ARTICLE	IF	CITATIONS
127	Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 970-977.	2.8	31
128	Fine mapping of hepatitis B virus pre- $\epsilon$ S deletion and its association with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1373-1381.	3.9	31
129	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	7.3	30
130	Evolution of Hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. <i>Journal of General Virology</i> , 2006, 87, 39-49.	2.9	30
131	Influence of Metabolic Syndrome, Viral Genotype and Antiviral Therapy on Superimposed Fatty Liver Disease in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-415.	1.0	30
132	Noninvasive Diagnosis of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler Impedance Index. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1199-1206.e1.	4.4	29
133	Esophageal Varices: Noninvasive Diagnosis with Duplex Doppler US in Patients with Compensated Cirrhosis. <i>Radiology</i> , 2008, 248, 132-139.	7.3	29
134	Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. <i>Antiviral Therapy</i> , 2009, 14, 1157-1163.	1.0	29
135	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 589-598.	3.7	29
136	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	3.9	29
137	Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women. <i>Hepatology</i> , 2002, 36, 156-163.	7.3	28
138	Hepatitis B Virus Basal Core Promoter Mutation and DNA Load Correlate with Expression of Hepatitis B Core Antigen in Patients with Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2009, 199, 742-749.	4.0	28
139	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 710-717.	2.8	28
140	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Gut</i> , 2022, 71, 176-184.	12.1	28
141	Amebic Liver Abscess and Human Immunodeficiency Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2001, 33, 64-68.	2.2	27
142	Pegylated interferon $\alpha$ -2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. <i>Gut</i> , 2009, 58, 314-316.	12.1	27
143	Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: Clinical and mechanistic implications. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1629-1636.	2.8	27
144	Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 289-292.	5.8	27

#	ARTICLE	IF	CITATIONS
145	Elimination of Hepatitis B in Highly Endemic Settings: Lessons Learned in Taiwan and Challenges Ahead. <i>Viruses</i> , 2020, 12, 815.	3.3	27
146	Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase. <i>Hepatology</i> , 2019, 69, 1412-1425.	7.3	26
147	Hepatitis C Virus and Hepatitis B Virus Co-Infection. <i>Viruses</i> , 2020, 12, 741.	3.3	26
148	High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. <i>Journal of Medical Virology</i> , 2007, 79, 1674-1678.	5.0	25
149	Incidence and risk analysis of aortic aneurysm and aortic dissection among patients with systemic lupus erythematosus: a nationwide population-based study in Taiwan. <i>Lupus</i> , 2014, 23, 665-671.	1.6	25
150	Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 7718.	3.3	25
151	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 461-468.e2.	4.4	24
152	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. <i>Liver International</i> , 2020, 40, 758-768.	3.9	24
153	Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. <i>Journal of Medical Virology</i> , 2004, 74, 237-245.	5.0	23
154	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1059-1067.	1.0	23
155	Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study. <i>European Journal of Neurology</i> , 2012, 19, 746-751.	3.3	23
156	Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1690-1698.	3.7	23
157	Origin of serum hepatitis B virus in acute exacerbation: Comparison with HBV in the liver and from other exacerbation. <i>Hepatology</i> , 2004, 40, 310-317.	7.3	22
158	Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 64-69.	2.0	22
159	Milder clinical manifestation of scrub typhus in Kinmen, Taiwan. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 201-207.	1.7	22
160	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Scientific Reports</i> , 2018, 8, 13699.	3.3	22
161	Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 2955.	3.3	22
162	Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. <i>Liver International</i> , 2005, 25, 214-219.	3.9	21

#	ARTICLE	IF	CITATIONS
163	Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2010, 4, 585-593.	4.2	21
164	Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon $\gamma$ signalling pathway. <i>Gut</i> , 2011, 60, 99-107.	12.1	21
165	Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. <i>Journal of Viral Hepatitis</i> , 2011, 18, e482-e490.	2.0	21
166	Treatment of patients with dual hepatitis $\gamma$ virus and hepatitis $\beta$ virus infection: Resolved and unresolved issues. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 26-30.	2.8	21
167	Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients. <i>Scientific Reports</i> , 2016, 6, 31349.	3.3	21
168	Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers. <i>Molecular Carcinogenesis</i> , 2017, 56, 425-435.	2.7	21
169	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020, 27, 568-575.	2.0	21
170	Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy. <i>Hepatology International</i> , 2022, 16, 211-253.	4.2	21
171	Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis $\gamma$ virus infection in Taiwan: a prospective study. <i>Liver International</i> , 2003, 23, 148-155.	3.9	20
172	Characterization of interleukin 8 in woodchucks with chronic hepatitis B and hepatocellular carcinoma. <i>Genes and Immunity</i> , 2009, 10, 27-36.	4.1	20
173	Plasma Adipokines and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus-Infected Carriers: A Prospective Study in Taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1659-1671.	2.5	20
174	Synergistic Effect of Hyperglycemia and Helicobacter pylori Infection Status on Colorectal Adenoma Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2744-2750.	3.6	20
175	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. <i>Hepatology International</i> , 2021, 15, 338-349.	4.2	20
176	Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 908-918.	3.7	20
177	Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. <i>Gut and Liver</i> , 2017, 11, 590-603.	2.9	20
178	A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. <i>Liver International</i> , 2008, 28, 1034-1041.	3.9	19
179	Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection. <i>PLoS ONE</i> , 2013, 8, e55916.	2.5	19
180	Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1480-1489.	3.7	19

#	ARTICLE	IF	CITATIONS
181	Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 306-316.	3.7	19
182	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , 2020, 115, 1226-1235.	0.4	19
183	The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. <i>Journal of Hepatology</i> , 2008, 49, 899-907.	3.7	18
184	Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 591-597.	4.2	18
185	Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. <i>Medicine (United States)</i> , 2016, 95, e2995.	1.0	18
186	Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. <i>Radiology</i> , 2018, 288, 293-299.	7.3	18
187	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 569-577.	3.1	18
188	Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses. <i>PLoS ONE</i> , 2011, 6, e20752.	2.5	18
189	Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan. <i>Intervirology</i> , 2007, 50, 310-315.	2.8	17
190	Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study. <i>European Journal of Human Genetics</i> , 2009, 17, 1250-1259.	2.8	17
191	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2332-8.	3.0	17
192	Hyperglycemia combined <i>Helicobacter pylori</i> infection increases risk of synchronous colorectal adenoma and carotid artery plaque. <i>Oncotarget</i> , 2017, 8, 108655-108664.	1.8	17
193	Decreased Colorectal Adenoma Risk After <i>Helicobacter pylori</i> Eradication: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 2105-2113.	5.8	17
194	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , 2020, 9, 207-220.	7.7	17
195	Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. <i>Oncogene</i> , 2006, 25, 3219-3224.	5.9	16
196	Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 153-160.	2.0	16
197	Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1242-1249.	2.8	16
198	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 3718.	3.3	16

#	ARTICLE	IF	CITATIONS
199	Mother-to-infant transmission of hepatitis B virus: challenges and perspectives. <i>Hepatology International</i> , 2017, 11, 481-484.	4.2	16
200	A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 291-297.	2.8	16
201	Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1476-1482.	1.7	16
202	Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 352-357.	2.8	15
203	Use of azathioprine for graft-vs-host disease is the major risk for development of secondary malignancies after haematopoietic stem cell transplantation: a nationwide population-based study. <i>British Journal of Cancer</i> , 2015, 112, 177-184.	6.4	15
204	Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase. <i>American Journal of Gastroenterology</i> , 2022, 117, 748-757.	0.4	15
205	Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. <i>Journal of Viral Hepatitis</i> , 2006, 13, 387-395.	2.0	14
206	Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan. <i>Liver International</i> , 2007, 27, 983-988.	3.9	14
207	The risky body mass index ranges for significant hepatitis B viral load: A campus-based study. <i>Obesity Research and Clinical Practice</i> , 2012, 6, e31-e38.	1.8	14
208	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. <i>Liver International</i> , 2014, 34, e71-9.	3.9	14
209	Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. <i>Journal of Gastroenterology</i> , 2014, 49, 356-362.	5.1	14
210	Perspectives on dual hepatitis B and C infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 298-305.	1.7	14
211	Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 697-704.	1.7	14
212	Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. <i>Movement Disorders</i> , 2019, 34, 1882-1890.	3.9	14
213	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1620-1625.	2.8	14
214	End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2004, 10, 3574.	3.3	14
215	Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. <i>Hepatology International</i> , 2011, 5, 814-821.	4.2	13
216	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. <i>Scientific Reports</i> , 2015, 5, 17410.	3.3	13

#	ARTICLE	IF	CITATIONS
217	Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2016, 64, 720-731.	7.3	13
218	How Does Aging Affect Presentation and Management of Biliary Stones?. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 2330-2335.	2.6	13
219	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. <i>Scientific Reports</i> , 2017, 7, 1728.	3.3	13
220	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0209299.	2.5	13
221	<i>Helicobacter pylori</i> infection combined with non-alcoholic fatty liver disease increase the risk of atherosclerosis. <i>Medicine (United States)</i> , 2019, 98, e14672.	1.0	13
222	Association of Adjuvant Antiviral Therapy with Risk of Cancer Progression and Deaths in Patients with Hepatitis-B-Virus-Related Hepatocellular Carcinoma following Curative Treatment: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2014, 9, e102051.	2.5	13
223	Sofosbuvir/Velpatasvir for Hepatitis B Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. <i>Infectious Diseases and Therapy</i> , 2022, 11, 485-500.	4.0	13
224	A forgotten population with chronic hepatitis C infection: Subjects coinfecting with hepatitis B virus. <i>Hepatology</i> , 2004, 40, 266-266.	7.3	12
225	Differential Clinical and Virologic Impact of Hepatitis B Virus Genotypes B and C on HIV-Coinfected Patients Receiving Lamivudine-Containing Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2012, 54, 548-555.	5.8	12
226	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. <i>Hepatology International</i> , 2015, 9, 35-42.	4.2	12
227	Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1478-1487.	1.7	12
228	Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. <i>Antiviral Therapy</i> , 2009, 14, 203-210.	1.0	12
229	Allergic rhinitis and risk of erectile dysfunction – a nationwide population-based study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 440-445.	5.7	11
230	Impact of Genetic Heterogeneity in Polymerase of Hepatitis B Virus on Dynamics of Viral Load and Hepatitis B Progression. <i>PLoS ONE</i> , 2013, 8, e70169.	2.5	11
231	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 589-597.	4.0	11
232	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 410-417.	2.8	11
233	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 556-564.	1.7	11
234	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 331-339.	3.7	11



#	ARTICLE	IF	CITATIONS
235	Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroconversion in Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 301-313.	3.7	11
236	Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. <i>Journal of Medical Virology</i> , 2011, 83, 1212-1220.	5.0	10
237	Clinical presentations of patients from different age cohorts with biliary tract stone diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1614-1619.	2.8	10
238	Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2020, 59, 1269-1279.	2.7	10
239	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2884-2892.	2.8	10
240	Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. <i>Journal of the Formosan Medical Association</i> , 2021, , .	1.7	10
241	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	1.0	10
242	Lack of Interferon Sensitivity-Determining Region in the Genome of Hepatitis B Virus Genotype Ba. <i>Antiviral Therapy</i> , 2004, 9, 895-903.	1.0	10
243	Molecular cloning and expression of woodchuck granulocyte-macrophage colony stimulating factor. <i>Journal of Medical Virology</i> , 2001, 65, 567-575.	5.0	9
244	Kinetics of Hepatitis B Virus Reactivation After Chemotherapy: More Questions Than Answers. <i>Gastroenterology</i> , 2006, 131, 1656.	1.3	9
245	Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand. <i>Hepatology International</i> , 2009, 3, 453-460.	4.2	9
246	IL-21R Gene Polymorphisms and Serum IL-21 Levels Predict Virological Response to Interferon-Based Therapy in Asian Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-8.	1.0	9
247	Identification of a liver cirrhosis signature in plasma for predicting hepatocellular carcinoma risk in a population-based cohort of hepatitis B carriers. <i>Molecular Carcinogenesis</i> , 2014, 53, 58-66.	2.7	9
248	Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. <i>Hepatology International</i> , 2014, 8, 382-394.	4.2	9
249	Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2017, 216, S757-S764.	4.0	9
250	Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 184-197.	7.3	9
251	Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. <i>JHEP Reports</i> , 2021, 3, 100254.	4.9	9
252	Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 575-588.	8.9	9



#	ARTICLE	IF	CITATIONS
253	Changing epidemiology of liver disease in Asia: Dual infection of HBV and HCV. Liver International, 2022, 42, 1945-1954.	3.9	9
254	Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. Alimentary Pharmacology and Therapeutics, 2021, , .	3.7	9
255	Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 2800-2808.	4.4	9
256	Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology, 2023, 21, 424-434.e5.	4.4	9
257	Hepatocellular carcinoma after treatment cessation in non- $\epsilon$ irrhotic HBeAg- $\epsilon$ negative chronic hepatitis B: A multicentre cohort study. Liver International, 2022, 42, 541-550.	3.9	9
258	Subgenotypes of Hepatitis B Virus Genotype C in Taiwan. Journal of Infectious Diseases, 2005, 192, 1308-1309.	4.0	8
259	Mixed hepatitis B virus genotype infections: The more, the worse?. Hepatology, 2006, 44, 770-770.	7.3	8
260	Disease Progression in a Patient with Nonalcoholic Steatohepatitis. Journal of the Formosan Medical Association, 2008, 107, 816-821.	1.7	8
261	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na $\tilde{v}$ e Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. Scientific Reports, 2015, 5, 15255.	3.3	8
262	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. Scientific Reports, 2020, 10, 9180.	3.3	8
263	Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. Journal of the Formosan Medical Association, 2021, , .	1.7	8
264	Hepatitis B virus Quantification and Detection of YMDD Mutants in a Single Reaction by Real-Time PCR and Annealing Curve Analysis. Antiviral Therapy, 2008, 13, 469-480.	1.0	8
265	Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. Liver International, 2007, 27, 235-239.	3.9	7
266	Hepatitis B virus genotype: What should the clinician know?. Current Hepatitis Reports, 2007, 6, 17-23.	0.3	7
267	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 102-109.	2.8	7
268	Peginterferon plus weight-based ribavirin for treatment-na $\tilde{v}$ e hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. Scientific Reports, 2015, 5, 11710.	3.3	7
269	Advanced Hepatic Fibrosis and Steatosis Are Associated With Persistent Alanine Aminotransferase Elevation in Chronic Hepatitis C Patients Negative for Hepatitis C Virus RNA During Pegylated Interferon Plus Ribavirin Therapy. Journal of Infectious Diseases, 2015, 211, 1429-1436.	4.0	7
270	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non- $\epsilon$ irrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1977-1983.	2.8	7

#	ARTICLE	IF	CITATIONS
271	Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 887-896.	2.0	7
272	Molecular assays for hepatitis B virus infection. <i>Hepatology</i> , 2003, 38, 1311-1311.	7.3	6
273	Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series. <i>Clinical Therapeutics</i> , 2006, 28, 1327-1334.	2.5	6
274	Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. <i>Journal of Medical Virology</i> , 2009, 81, 588-593.	5.0	6
275	Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. <i>Hepatology International</i> , 2013, 7, 171-179.	4.2	6
276	Increased cancer risk in patients with haemophilia A: a nationwide population-based 14-year study in Taiwan. <i>Haemophilia</i> , 2014, 20, 741-746.	2.1	6
277	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 953-960.	1.7	6
278	Increased risk of pulmonary tuberculosis in patients with gastroesophageal reflux disease. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 265-270.	1.2	6
279	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1345-1352.	4.0	6
280	Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 588-595.	3.1	6
281	Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. <i>Hepatology Research</i> , 2020, 50, 1109-1117.	3.4	6
282	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.4	6
283	Effects of <i>Helicobacter pylori</i> infection in gastrointestinal tract malignant diseases: From the oral cavity to rectum. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 55-74.	2.0	6
284	Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-15.	1.0	6
285	Interferon-based therapy for dialysis patients with chronic hepatitis C: Progress and challenges (Editorial). <i>Nephrology</i> , 2007, 12, 8-10.	1.6	5
286	Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: Story beyond A1762T/G1764A mutations. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 347-350.	2.8	5
287	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. <i>Antiviral Therapy</i> , 2011, 16, 227-235.	1.0	5
288	Associated factors and clinical implications of serum aminotransferase elevation in scrub typhus. <i>Journal of Microbiology, Immunology and Infection</i> , 2016, 49, 941-946.	3.1	5

#	ARTICLE	IF	CITATIONS
289	NOhep: Toward Global Control of Hepatitis B Virus Infection—An Introduction. <i>Journal of Infectious Diseases</i> , 2017, 216, S749-S749.	4.0	5
290	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. <i>International Journal of Cancer</i> , 2020, 147, 901-908.	5.1	5
291	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1871-1875.	1.7	5
292	Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients. <i>Hepatology International</i> , 2021, 15, 582-592.	4.2	5
293	Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. <i>PLoS ONE</i> , 2015, 10, e0137852.	2.5	5
294	Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment. <i>Clinical Infectious Diseases</i> , 2022, 75, 453-459.	5.8	5
295	Pegylated Interferons for the Treatment of Chronic Hepatitis B. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2006, 1, 85-94.	0.8	4
296	Implications of Hepatitis B Virus Genomic Variations on Treatment Outcomes. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2010, 8, 280-288.	0.2	4
297	Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 295-299.	1.7	4
298	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 497-504.	1.7	4
299	Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 933-940.	1.7	4
300	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 5372.	3.3	4
301	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , 2021, 15, 1109-1121.	4.2	4
302	Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF- $\kappa$ B signaling and tumor progression in a woodchuck hepatocellular carcinoma model. <i>Oncotarget</i> , 2016, 7, 47173-47185.	1.8	4
303	Immunopathogenesis of Acute Flare of Chronic Hepatitis B: With Emphasis on the Role of Cytokines and Chemokines. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1407.	4.1	4
304	Helicobacter pylori infection and increased diabetes prevalence were the risks of colorectal adenoma for adults. <i>Medicine (United States)</i> , 2021, 100, e28156.	1.0	4
305	Reply.. <i>Hepatology</i> , 2007, 46, 947-949.	7.3	3
306	Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy. <i>Digestive and Liver Disease</i> , 2009, 41, 322-323.	0.9	3

#	ARTICLE	IF	CITATIONS
307	758 ENTECAVIR PLUS PEGINTERFERON alfa-2a vs. ENTECAVIR ALONE IN THE TREATMENT OF HEPATITIS B e ANTIGEN-POSITIVE CHRONIC HEPATITIS B: AN INTERIM REPORT. <i>Journal of Hepatology</i> , 2013, 58, S308.	3.7	3
308	Tu1502 “ Ledipasvir/Sofosbuvir is Highly Effective and Safe in Patients with Chronic Hepatitis B Virus and Hepatitis C Virus Coinfection: Final Study Results. <i>Gastroenterology</i> , 2019, 156, S-1345.	1.3	3
309	Relationship between serum gamma-glutamyl transferase level and colorectal adenoma. <i>PLoS ONE</i> , 2020, 15, e0240445.	2.5	3
310	Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. <i>Advances in Digestive Medicine</i> , 2020, , .	0.2	3
311	Effects and safety of body positioning on back pain after transcatheter arterial chemoembolization in people with hepatocellular carcinoma: A randomized controlled study. <i>International Journal of Nursing Studies</i> , 2020, 109, 103641.	5.6	3
312	Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2247-2254.	2.8	3
313	Investigating the prevalence and clinical effects of hepatitis delta viral infection in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 901-908.	3.1	3
314	Gut-flora metabolites is not associated with synchronous carotid artery plaque and non-alcoholic fatty liver disease in asymptomatic adults. <i>Medicine (United States)</i> , 2021, 100, e27048.	1.0	3
315	Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. <i>Antiviral Therapy</i> , 2004, 9, 895-903.	1.0	3
316	Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis. <i>Antiviral Therapy</i> , 2008, 13, 469-80.	1.0	3
317	Clinical Significance of Occult Hepatitis B Virus Infection Cannot Be Overlooked. <i>Clinical Infectious Diseases</i> , 2006, 42, 583-584.	5.8	2
318	Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. <i>Hepatology International</i> , 2012, 6, 598-605.	4.2	2
319	Micro-evolution of the hepatitis <sc>B</sc> virus genome in hepatitis <sc>B</sc> e antigen-positive carriers: Comparison of genotypes <sc>B</sc> and <sc>C</sc> at various immune stages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 172-177.	2.8	2
320	Immortal time bias in retrospective analysis: comment on “Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma”™. <i>Blood Cancer Journal</i> , 2015, 5, e283-e283.	6.2	2
321	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4 “6 infection: Real-world evidence from a nationwide registry in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1567-1578.	1.7	2
322	Metabolic syndrome on top of chronic hepatitis B: the more, the worse?. <i>Gut</i> , 2010, 59, 276-277.	12.1	1
323	Transabdominal Ultrasound Finding and Acute Hepatocellular Injury in Different Cohorts of Elderly Adults with and without Common Bile Duct Stones. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 1221-1224.	2.6	1
324	Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1427-1428.	3.7	1

#	ARTICLE	IF	CITATIONS
325	Age and gender may be the key points in hyperglycemic patients with <i>Helicobacter pylori</i> infection combined colorectal adenoma. <i>Helicobacter</i> , 2018, 23, e12473.	3.5	1
326	Occult Hepatitis B Infection. , 2021, , 411-425.		1
327	Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9380.	4.1	1
328	Kinetics of Hepatitis B Surface Antigen in Pregnant Women with and without Tenofovir Disoproxil Fumarate. <i>Journal of Viral Hepatitis</i> , 2021, , .	2.0	1
329	Sequential Combination Therapy for Chronic Hepatitis B: More Challenges to Be Tackled. <i>American Journal of Gastroenterology</i> , 2007, 102, 1544-1544.	0.4	0
330	Acute Fatty Liver of Pregnancy with Concurrent Acute Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, 2663-2665.	0.4	0
331	Research Highlights: Pharmacogenomics of chronic hepatitis C. <i>Pharmacogenomics</i> , 2009, 10, 1039-1042.	1.3	0
332	Simple predictor for anemia in chronic hepatitis C patients receiving peginterferon plus ribavirin. <i>Advances in Digestive Medicine</i> , 2016, 3, 1-2.	0.2	0
333	A simple non-invasive test for ruling out cirrhosis in chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 495-496.	8.1	0
334	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1287-1291.	2.8	0
335	Treatment of Hepatitis C Virus Infection: Past, Present and Future. , 2012, , 341-371.		0